Industry News

Pharmaconex West Africa, the latest expansion of the successful Pharmaconex event series, will take place from 22-24 April 2024 at the Landmark Centre in Lagos, Nigeria.

The event will focus on Active Pharmaceutical Ingredients (APIs) & Generic APIs, Machinery & Process, Packaging Materials, and Finished Dosage Forms (FDF) and is open to all businesses involved in the pharmaceutical and medical laboratory sectors, including manufacturers, distributors, suppliers, consultants, researchers, and regulators.

Chairwoman of ACDIMA International Olfat Ghorab issued a press statement Tuesday announcing the beginning of the pilot operation of the $1-billion worth factory specialized in cancer drugs in collaboration with an Italian firm.

Source: egypttoday

The General Authority for Free Zones and Investment (GAFI) hosted Tuesday the signing of 14 agreements worth $7.7 billion between the Egyptian and Saudi sides in the sectors of infrastructure, logistics, port management, food industries, pharmaceuticals, traditional energy, renewable energy, e-payment, digital financial and information solutions.

Source: egypttoday

Led by Alliance president Dr. Becky Upton, the 13 next-generation leaders from large global pharmaceutical companies reflect the diversity of membership viewpoints. The Council will explore common challenges at a grassroots level and seed ideas for new pre-competitive projects aligned with the Alliance’s strategic themes: Emerging sciences and Technology, Improving the Efficiency and Effectiveness of R&D, and Empowering the Patient.

Source: european pharmaceutical manufacturer 

Sustainability is at the heart of the pharmaceutical industry’s day-to-day operations, with many skilled individuals working in sustainability roles.  We are starting to see initiatives from companies all across the world, from investment in renewables, to low-carbon inhalers, to net zero buildings, and some examples are featured here, demonstrating their commitment to tackling the challenges in building a greener pharmaceutical industry in the UK.

Source: abpi

First founded in 2019 as a new regulatory body independent from Egypt’s Ministry of Health, the Egyptian Drug Authority (EDA) has made significant progress over the last three years. Now recognised as one of the MEA region’s leading regulators, the EDA can point to several notable successes in Egypt’s battle against the COVID-19 pandemic.

Source: Pharmaboardroom

Complying with Irish takeover rules, Amgen alerted the London Stock Exchange Friday that “any offer by Amgen for Horizon is, or is likely to be, solely in cash.” Naturally, the company caveated that there can “be no certainty” an offer will materialize.

Source: FIERCE Pharma

Dec 1 (Reuters) - The U.S. health regulator on Thursday declined to approve a treatment from Y-mAbs Therapeutics (YMAB.O) for a rare form of nerve cancer in pediatric patients, dragging the company's shares down 16% inextended trading. 

Source: Reuters

“Local pharma manufacturing in the MENA region represents between 32-57 percent of the consumed pharma packages. Egypt is one of the pioneering countries in terms of pharma industry localisation compared to other countries in the region, as local pharma production to consumption ratio in the Egyptian market is over 65 percent,”

Source: Ahram Online

Under the umbrella of its Vision 2030 economic transformation plan, Egypt is making strides towards covering its over 100 million citizens through a universal healthcare insurance scheme that has already been rolled out on a pilot basis in certain areas of the country.

Source: Pharmaboardroom

"The exhibition provides great opportunities to build relationships with prospects and existing clients as well as form new business networks," said Ahmed Hany, an engineer with Cairo-based Nama Group, which is an agent, distributor, and producer of quality products including medicines.

Source: Xinhua

The COVID-19 pandemic has changed the world – and the biopharma industry. The industry has adopted new technologies and approaches to drug development – and has learned that it is possible to bring new therapies to patients in significantly reduced timelines. 

Source: The Medicine Maker